Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How
  • CME
  • MOC

Watch this CME/MOC-certified on-demand Webcast of a CCO symposium at ASCP 2019 to gain insights from both medical oncology and pathology experts on the optimal use of predictive biomarkers for immune checkpoint inhibitors in the care of patients with lung cancer.
H. Jack West, MD
Program Director
Sanjay Mukhopadhyay, MD
Sandip P. Patel, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
US Physicians: maximum of 1.0 Medical Knowledge MOC point(s)
Released: October 8, 2019 Expiration: October 7, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the clinical utility of predictive biomarkers for immune checkpoint inhibitor response in lung cancer by line of therapy, available therapeutic alternatives, and health economic considerations
  • Compare and contrast the different methodologies and assays for identifying biomarkers of response to immune checkpoint inhibitors in different lung cancer histologies and treatment settings
  • Implement best practices for biomarker testing/interpretation of results to guide treatment selection in different lung cancer histologies and treatment settings
  • Summarize ongoing research regarding the utility of biomarkers, PD-L1, MSI/MMR, tumor mutational burden, DNA damage repair, T-cell functional state, composite biomarkers, or other host factors predictive of response to and/or toxicities associated with immune checkpoint inhibitors

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

H. Jack West, MD

Associate Clinical Professor
City of Hope Comprehensive Cancer Center
Duarte, California

H. Jack West, MD, has disclosed that he has received consulting fees from Ariad/Takeda, Bristol-Myers Squibb, Celgene, Genentech/Roche, and Merck and fees for non-CME/CE services from Ariad/Takeda, Genentech/Roche, Lilly, and Merck.

Faculty

Sanjay Mukhopadhyay, MD

Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Cleveland, Ohio

Sanjay Mukhopadhyay, MD, has no relevant conflicts of interest to report.
Sandip P. Patel, MD

Associate Professor
Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California

Sandip P. Patel, MD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Illumina, Lilly, and Tempus.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse/partner has ownership interest in and receives a salary from AstraZeneca.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Goal

The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology Continuing Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Learners must complete the post-test with a passing score of 70%. Physicians may follow the post test link provided at the end of the activity evaluation to claim ABPath MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 08, 2019, through October 07, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Clinical Care Options (CCO), download this PDF summarizing HER2, HER3, and TROP2 testing and targeted therapeutics

Mark D. Pegram, MD Michael F. Press, MD, PhD Released: July 30, 2020

From Clinical Care Options (CCO), watch this video featuring expert presentations on new and emerging biomarkers key to lung cancer care

Edward S. Kim, MD, FACP
Program Director
Leora Horn, MD, MSc, FRCPC
Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: July 30, 2020 Expired: July 29, 2021

Watch expert faculty discuss updated testing and treatment options for METex14-positive NSCLC in this video from Clinical Care Options (CCO)

D. Ross Camidge, MD, PhD person default Luis Paz-Ares, MD, PhD Karen L. Reckamp, MD, MS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: July 24, 2020 Expired: July 23, 2021

Downloadable PDF resource to aid treatment discussions with patients with advanced NSCLC including capturing their input on goals and preferences, from Clinical Care Options (CCO)

Released: July 24, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Genentech
Merck Sharp & Dohme Corp

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?